Jung-Rern Jiang
Research Subjects
Jung-Rern Jiang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Shiao‐Yu Yen
Department of Medical Affairs Section Public Health Bureau Yunlin County Taiwan
2 shared publications- Ching-Hui Chen
Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University Hospital, Taipei, Taiwan, ROC; Nuwa Fertility Center, Taipei, Taiwan, ROC
1 shared publication - Hao-Chien Wang
College of Medicine, National Taiwan University, Taipei, Taiwan
1 shared publication Hsiao-Chien Liu
Department of Respiratory Therapist, St. Joseph's Hospital, #74 Sinsheng Rd, Huwei, 632, Yunlin County, Taiwan
1 shared publicationHsiao‐Chien Liu
Department of Respiratory Therapist St Joseph's Hospital Yunlin County Taiwan
1 shared publication- Jann-Yuan Wang
Department of Internal Medicine, National Taiwan University Hospital
1 shared publication
Latest Publications
- 13 March 2018
- Published by Springer Nature in Journal of Anesthesia
- Vol. 32 (3) , 351-359
Endotracheal tube size to leakage ventilation and tracheal dilatation
This study analyzed the clinical factors with the aim to determine the relationship between endotracheal tube (ETT) size and leakage ventilation (LV) and tracheal dilatation.
- 13 March 2018
- Published by Springer Nature in Journal of Anesthesia
- Vol. 32 (3) , 351-359
Endotracheal tube size to leakage ventilation and tracheal dilatation
This study analyzed the clinical factors with the aim to determine the relationship between endotracheal tube (ETT) size and leakage ventilation (LV) and tracheal dilatation.
- 24 March 2014
- Published by Wiley in Respirology
- Vol. 19 (4) , 576-582
Predicting weaning and extubation outcomes in long‐term mechanically ventilated patients using the modified Burns Wean Assessment Program scores
Background and objective: A number of clinical factors play pivotal roles in weaning and successful extubation of patients requiring long‐term mechanical ventilator (LTMV) support. Many patients fail extubation even after passing weaning protocols and spontaneous breathing trials. This study aimed to assess the effectiveness of using a modified Burns Wean Assessment Program (m‐BWAP) scoring instrument to predict extubation outcome in patients requiring LTMV.Methods: All patients with a diagnostic coding for respiratory failure requiring LTMV for longer than 21 days over a 5‐year period in a single centre (total 527 patients) were included. Advanced practice nurses trained in the use of the m‐BWAP scored the items according to standard definitions. All patients were weaned by pressure support weaning and spontaneous breathing trails. Patients were divided into successful and unsuccessful groups according to the weaning and extubation outcomes. Baseline data, traditional weaning parameters and m‐BWAP of the groups were analysed. The sensitivity and specificity of m‐BWAP for predicting successful extubation were calculated.Results: Of the 527 patients included, 145 (27.5%) had successful weaning trials. Of the 130 patients extubated, 102 (78.5%) had successful extubation. The m‐BWAP score was higher in the patients with successful weaning trials and successful extubation outcome. Using a cut‐off value of 60, the sensitivity and specificity of the m‐BWAP to predict successful extubation were 81.4% and 82.1%, respectively. This was better than traditional weaning parameters.Conclusions: The m‐BWAP is a good predictor for weaning and extubation outcome in patients requiring LTMV for longer than 21 days.
- 24 March 2014
- Published by Wiley in Respirology
- Vol. 19 (4) , 576-582
Predicting weaning and extubation outcomes in long‐term mechanically ventilated patients using the modified Burns Wean Assessment Program scores
Background and objective: A number of clinical factors play pivotal roles in weaning and successful extubation of patients requiring long‐term mechanical ventilator (LTMV) support. Many patients fail extubation even after passing weaning protocols and spontaneous breathing trials. This study aimed to assess the effectiveness of using a modified Burns Wean Assessment Program (m‐BWAP) scoring instrument to predict extubation outcome in patients requiring LTMV.Methods: All patients with a diagnostic coding for respiratory failure requiring LTMV for longer than 21 days over a 5‐year period in a single centre (total 527 patients) were included. Advanced practice nurses trained in the use of the m‐BWAP scored the items according to standard definitions. All patients were weaned by pressure support weaning and spontaneous breathing trails. Patients were divided into successful and unsuccessful groups according to the weaning and extubation outcomes. Baseline data, traditional weaning parameters and m‐BWAP of the groups were analysed. The sensitivity and specificity of m‐BWAP for predicting successful extubation were calculated.Results: Of the 527 patients included, 145 (27.5%) had successful weaning trials. Of the 130 patients extubated, 102 (78.5%) had successful extubation. The m‐BWAP score was higher in the patients with successful weaning trials and successful extubation outcome. Using a cut‐off value of 60, the sensitivity and specificity of the m‐BWAP to predict successful extubation were 81.4% and 82.1%, respectively. This was better than traditional weaning parameters.Conclusions: The m‐BWAP is a good predictor for weaning and extubation outcome in patients requiring LTMV for longer than 21 days.
- 27 January 2011
- Published by Wiley in Respirology
- Vol. 16 (2) , 308-313
Increased prevalence of primary drug‐resistant pulmonary tuberculosis in immunocompromised patients
Drug-resistant tuberculosis (DR-TB) is difficult and expensive to treat, and is associated with a higher rate of mortality. We conducted a long-term survey to compare the prevalence of primary drug-resistance, adverse effects of drugs and duration of treatment in immunocompetent and immunocompromised patients. Factors associated with primary drug resistance were also investigated. The patients studied had culture-confirmed pulmonary TB but had not previously received anti-TB treatment. These patients were divided into immunocompetent (IMCPe) and immunocompromised (IMCPr) groups. Baseline data, the prevalence of DR-TB, duration of treatment and adverse effects of drugs were analysed. The rates of resistance to individual first-line anti-TB drugs in the two groups and in subgroups of the IMCPr group were calculated. Multinomial regression analysis was performed to investigate the risk factors associated with primary DR-TB. Among the 394 patients, 159 (40.4%) were in the IMCPr group. The baseline data for the two groups were similar, except that the IMCPr group was slightly older. The prevalence of drug-resistance was higher in the IMCPr group (25.8% vs 17.0%, OR 1.69, 95% CI: 1.04-2.77), especially for isoniazid, rifampicin and streptomycin, and patients with liver cirrhosis, malignancies and those receiving immunosuppressants. The incidence of adverse drug effects was similar in the IMCPr and IMCPe groups. Multinomial regression analysis showed that being in the IMCPr group, and especially treatment with immunosuppressants, were independent risk factors for DR-TB. Immunocompromised patients with underlying diseases had an increased prevalence of primary pulmonary DR-TB but a similar incidence of drug-related adverse effects. Diagnosis and investigation of drug-resistance is important before initiating anti-TB treatment in this group of patients.
- 27 January 2011
- Published by Wiley in Respirology
- Vol. 16 (2) , 308-313
Increased prevalence of primary drug‐resistant pulmonary tuberculosis in immunocompromised patients
Drug-resistant tuberculosis (DR-TB) is difficult and expensive to treat, and is associated with a higher rate of mortality. We conducted a long-term survey to compare the prevalence of primary drug-resistance, adverse effects of drugs and duration of treatment in immunocompetent and immunocompromised patients. Factors associated with primary drug resistance were also investigated. The patients studied had culture-confirmed pulmonary TB but had not previously received anti-TB treatment. These patients were divided into immunocompetent (IMCPe) and immunocompromised (IMCPr) groups. Baseline data, the prevalence of DR-TB, duration of treatment and adverse effects of drugs were analysed. The rates of resistance to individual first-line anti-TB drugs in the two groups and in subgroups of the IMCPr group were calculated. Multinomial regression analysis was performed to investigate the risk factors associated with primary DR-TB. Among the 394 patients, 159 (40.4%) were in the IMCPr group. The baseline data for the two groups were similar, except that the IMCPr group was slightly older. The prevalence of drug-resistance was higher in the IMCPr group (25.8% vs 17.0%, OR 1.69, 95% CI: 1.04-2.77), especially for isoniazid, rifampicin and streptomycin, and patients with liver cirrhosis, malignancies and those receiving immunosuppressants. The incidence of adverse drug effects was similar in the IMCPr and IMCPe groups. Multinomial regression analysis showed that being in the IMCPr group, and especially treatment with immunosuppressants, were independent risk factors for DR-TB. Immunocompromised patients with underlying diseases had an increased prevalence of primary pulmonary DR-TB but a similar incidence of drug-related adverse effects. Diagnosis and investigation of drug-resistance is important before initiating anti-TB treatment in this group of patients.